This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Rofecoxib

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • this is a non-steroidal anti-inflammatory drug which was licensed for the symptomatic treatment osteoarthritis (1)
  • the sparing of the COX-1 isoenzyme should, in theory, result in reduced gastrointestinal side-effects and improves tolerability. However the evidence that COX-2 selectivity reduces the risk of serious upper gastrointestinal side effects, particularly gastrointestinal bleeding and ulcer perforation, points towards some reduction of risk but the advantage over conventional non-steroidal anti-inflammatory drugs appears small (1)

Note that there has been a voluntary worldwide withdrawal of the 'COX-2 selective NSAID' rofecoxib (Vioxx/VioxxAcute) by the manufacturer. This follows new clinical trial results showing an increased risk of confirmed serious thrombotic events (including myocardial infarction and stroke) compared to placebo, following long-term use (2)

Reference:

  1. Drug and Therapeutics Bulletin (2000), 38 (11), 81-86.
  2. Committee on Safety of Medicines (September 30th 2004). DOH Cascade.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.